MDKM Mdechem Inc (CE)

MDEChem, Inc. (PINK SHEETS:MDKM) is pleased to announce that this past Friday, January 20th 2005, it held a strategy meeting consisting of management, consultants, shareholders and others instrumental to the success of the Company. During the meeting, it was announced that the Company's 2004 & 2005 financials will be completed in the next couple of weeks which will lead to the Company making application to be listed on the OTC Bulletin Board. In addition to the Bulletin Board listing, the Company provided an update on Envirofuels LP, its operating partner and maker of the Diesel Fuel Catalyzer. "We addressed some very serious issues going forward as it relates to the success of MDEChem including participation with Envirofuels LP and also with the MDEChem's sister Company, Costa Rican based, M.E.D. Quimica S.A., the maker and marketer of Maxheal." stated Paul Sack, MDEChem's President and CEO. Maxheal is a wound healing gel that has numerous wound healing components which is used directly on a human's wound. Mr. Sack continued, "We flew in Dr. Enrique Feoli, the inventor of the Maxheal process, from Costa Rica to address the meetings participants, and he expanded on the numerous potential uses of the Maxheal formula for use not only in human applications but in the Animal Health sector." Dr. Feoli gave a detailed overview of all the potential uses of the Maxheal gel, which will be produced and then sold in the U.S. Since Maxheal has been selling for a minimum 5 year timeframe, FDA clearance is not necessary as this would be an over-the-counter product available in the U.S. MEDQ has had as its principal mission to develop innovative drug formulations based on a patented water-soluble basic molecule, which is owned by MDEChem. MEDQ has perfected a family of products that could be registered and introduced into the market in the near future. Most of the products have matching clinical studies and scientific evidence to back them up. Registration renewals and registration of new products can be accomplished from facilities in Costa Rica. Foreign markets could follow shortly after registration of products is secured. It is estimated that the asthma product within 6 months of concluding a pre-clinical and clinical study could be safely and efficaciously used in controlling asthma in children and adults worldwide. Resources for these actions are being pursued presently, not solely for sales purposes but also for seeking patent protection of the applications. MEDQ authenticated an innovative product for skin treatment in 1999. Since then MEDQ has established the complete safety of the product. The excellent record of safety of use on humans and the extremely favorable LD50 of the basic molecule greater than 20% better toxicity than substances considered by the EPA as safe. During late 2000 and early 2001, Dr. Feoli developed a family of hydrogels that according to a bio-availability study done in animals in early 2001 would function in a friendly way and in a much more efficaciously way than a solution. The gels could be employed additionally as controlled delivery system. A sanitary registration was filed in Costa Rica for the skin treatment gel developed by Dr. Feoli and it was approved on April 24th 2001. MDEChem, Inc. owns 100% of M.E.D. Quimica S.A. as of a July 26, 2004 Letter of Understanding which details each companies mission statement, plus all royalty, licensing and marketing arrangements for the manufacture and distribution of product worldwide. In regards to the Envirofuels LP Diesel Fuel Catalyzer, sales continue to grow. While the Company expects to make public a major railroad line purchase sometime in the near future, sales continue to mount with the addition of more smaller, local line railroads now totaling 30 across the U.S.A. NOTE: Safe Harbor Statements may contain "forward looking statements" under the Private Securities Litigation Reform Act of 1995. This announcement may contain "forward looking" statements. Although we believe that the statements contained herein are reasonable, no assurance can be guaranteed as to their accuracy, authenticity or prove correct. Always consult an Investment Advisor prior to investing.